Twinbeech Capital LP Abb Vie Inc. Transaction History

Twinbeech Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $27.7 Million - $31.5 Million	173,088 New	173,088 $31.5 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $3.45 Million - $4.28 Million	-26,152 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $2.81 Million - $3.55 Million	26,152 New	26,152 $3.54 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $6.53 Million - $7.41 Million	-61,358 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $6.46 Million - $7.19 Million	61,358 New	61,358 $6.91 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $3.71 Million - $5.01 Million	-46,139 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $3.96 Million - $4.65 Million	46,139 New	46,139 $4.04 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.